Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.

• Revenue in SEK (TTM)381.00k
• Net income in SEK-40.83m
• Incorporated2009
• Employees--

• Location
  Xintela ABScheeletorget 1LUND 223 81SwedenSWE
• Phone+46 462756500
• Websitehttps://www.xintela.se/